Form D · Biotechnology
Xalud Therapeutics, Inc.
Charlottesville, VA · CIK 0001646982
Offering snapshot reported Jun 2, 2021 · SEC filing
- Reported sold
- $18.2M Offering amount: $30M
- Investors reported
- Not reported Form D · investor count
- Minimum accepted
- Not reported Reported outside-investor minimum
- First sale
- Not reported As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 2, 2021 | Initial | $18,178,983 | No comparison | Not reported | SEC filing |
| Mar 30, 2020 | Initial | $5,000,000 | No comparison | 1 | SEC filing |
| Jul 16, 2015 | Initial | $7,300,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Not reported
- Exemptions
- Not reported
- Duration over one year
- Not reported
- Business combination
- Not reported
- Sales commissions
- Not reported
- Finders' fees
- Not reported
- Form D file number
- 021-401483
Source: Form D, filed Jun 2, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Raymond Chavez | Director, Executive |
| Stephen Collins | Director, Executive |
| John Forsayeth | Director |
| Peter Heinecke | Director |
| Paul B. Manning | Director |
| Diem Nguyen | Director, Executive |
| Jayson Rieger | Director |
| Sean Stalfort | Director |
| Linda Watkins | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
200 Garrett Street Suite S
Charlottesville, VA, 22902
Charlottesville, VA, 22902